CLD-202 / Calidi Biotherap - LARVOL DELTA

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer (Businesswire) - "Calidi Biotherapeutics...today announced the commitment of $25 million in Series B funding led by Jackson Investment Group ('JIG'), who has funded an initial investment of $5 million....The financing will enable Calidi to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications."

Financing • Oncology